315 related articles for article (PubMed ID: 28395440)
1. [Prognostic significance of blood count at the time of achieving morphologic leukemia-free state in adults with acute myeloid leukemia].
Ren X; Zhao T; Wang J; Zhu HH; Jiang H; Jia JS; Yang SM; Jiang B; Wang DB; Huang XJ; Jiang Q
Zhonghua Xue Ye Xue Za Zhi; 2017 Mar; 38(3):185-191. PubMed ID: 28395440
[No Abstract] [Full Text] [Related]
2. [Outcomes of adult patients with
Ren X; Zhao T; Wang J; Zhu HH; Jiang H; Jia JS; Yang SM; Jiang B; Wang DB; Huang XJ; Jiang Q
Zhonghua Xue Ye Xue Za Zhi; 2018 Jan; 39(1):15-21. PubMed ID: 29551027
[No Abstract] [Full Text] [Related]
3. [Minimal residual disease level predicts outcomes in the non-favorable risk patients with acute myeloid leukemia].
Ren X; Zhao T; Wang J; Zhu HH; Jiang H; Jia JS; Yang SM; Jiang B; Wang DB; Huang XJ; Jiang Q
Zhonghua Xue Ye Xue Za Zhi; 2017 Jul; 38(7):578-585. PubMed ID: 28810324
[No Abstract] [Full Text] [Related]
4. [Factors associated with early treatment response in adults with acute myeloid leukemia].
Ren X; Zhao T; Wang J; Zhu HH; Jiang H; Jia JS; Yang SM; Jiang B; Wang DB; Huang XJ; Jiang Q
Zhonghua Xue Ye Xue Za Zhi; 2017 Oct; 38(10):869-875. PubMed ID: 29166740
[No Abstract] [Full Text] [Related]
5. [Prognostic significance of early assessment of minimal residual disease in acute myeloid leukemia with mutated NPM1 patients].
Zhao T; Zhu HH; Wang J; Jia JS; Yang SM; Jiang H; Lu J; Chen H; Xu LP; Zhang XH; Jiang B; Ruan GR; Wang DB; Huang XJ; Jiang Q
Zhonghua Xue Ye Xue Za Zhi; 2017 Jan; 38(1):10-16. PubMed ID: 28219218
[No Abstract] [Full Text] [Related]
6. Salvage therapy in refractory acute myeloid leukemia: prediction of outcome based on analysis of prognostic factors.
Tavernier E; Le QH; Elhamri M; Thomas X
Leuk Res; 2003 Mar; 27(3):205-14. PubMed ID: 12537972
[TBL] [Abstract][Full Text] [Related]
7. Relation of clinical response and minimal residual disease and their prognostic impact on outcome in acute myeloid leukemia.
Chen X; Xie H; Wood BL; Walter RB; Pagel JM; Becker PS; Sandhu VK; Abkowitz JL; Appelbaum FR; Estey EH
J Clin Oncol; 2015 Apr; 33(11):1258-64. PubMed ID: 25732155
[TBL] [Abstract][Full Text] [Related]
8. [Treatment responses, outcomes, and prognostic factors associated with them in patients with secondary acute myeloid leukemia].
Ma L; Zhao T; Chen YY; Jiang H; Xu LP; Zhang XH; Wang Y; Sun YQ; Mo XD; Huang XJ; Jiang Q
Zhonghua Xue Ye Xue Za Zhi; 2023 Feb; 44(2):124-131. PubMed ID: 36948866
[No Abstract] [Full Text] [Related]
9. [Effectiveness analysis of HA based triple-drug regimen as induction chemotherapy in the treatment of acute myeloid leukemia and its relationship with karyotype].
Mi YC; Xue YP; Yu WJ; Liu SH; Zhao YZ; Meng QX; Bian SG; Wang JX
Zhonghua Xue Ye Xue Za Zhi; 2005 Dec; 26(12):705-9. PubMed ID: 16620570
[TBL] [Abstract][Full Text] [Related]
10. Prognostic implications of NPM1 mutations and FLT3 internal tandem duplications in Egyptian patients with cytogenetically normal acute myeloid leukemia.
Shamaa S; Laimon N; Aladle DA; Azmy E; Elghannam DM; Salem DA; Taalab MM
Hematology; 2014 Jan; 19(1):22-30. PubMed ID: 23540998
[TBL] [Abstract][Full Text] [Related]
11. [The relationship between induction chemotherapy cycles and prognosis in patients with acute myeloid leukemia].
Zhao T; Zhang Y; Yang S; Bao L; Wang J; Jiang H; Zhu H; Jia J; Lu J; Jiang B; Huang X; Jiang Q
Zhonghua Xue Ye Xue Za Zhi; 2015 Feb; 36(2):89-94. PubMed ID: 25778880
[TBL] [Abstract][Full Text] [Related]
12. [Comparison of efficacy and prognostic factors in elderly acute myelogenous patients with MA or CAG induction chemotherapy regimen].
Wang J; Jiang B; Jiang Q; Lu J; Zhu HH; Yang SM; Zhao T; Wen L; Bao L; Huang XJ; Jiang H
Zhonghua Xue Ye Xue Za Zhi; 2016 Mar; 37(3):194-200. PubMed ID: 27033755
[TBL] [Abstract][Full Text] [Related]
13. Different clinical importance of FLT3 internal tandem duplications in AML according to FAB classification: possible existence of distinct leukemogenesis involving monocyte differentiation pathway.
Koh Y; Park J; Ahn KS; Kim I; Bang SM; Lee JH; Yoon SS; Soon Lee D; Yiul Lee Y; Park S; Kim BK
Ann Hematol; 2009 Nov; 88(11):1089-97. PubMed ID: 19296110
[TBL] [Abstract][Full Text] [Related]
14. [Long-term outcomes of homoharringtonine, cytarabine, daunorubicin or idarubicin (HAD/HAI) as induction chemotherapy in de novo acute myeloid leukemia].
Qin T; Xu Z; Zhang Y; Lin Y; Ru K; Fang L; Zhang H; Pan L; Hu N; Qu S; Wang J; Xing R; Xiao Z
Zhonghua Xue Ye Xue Za Zhi; 2016 Feb; 37(2):94-9. PubMed ID: 27014976
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic experience of adult acute myeloid leukemia in a single institution of China and its relationship with chromosome karyotype.
Mi Y; Xue Y; Yu W; Liu S; Zhao Y; Meng Q; Bian S; Wang J
Leuk Lymphoma; 2008 Mar; 49(3):524-30. PubMed ID: 18297530
[TBL] [Abstract][Full Text] [Related]
16. Prognostic Parameters of Acute Myeloid Leukaemia at Presentation.
Jahic A; Iljazovic E; Hasic S; Arnautovic AC; Sabitovic D; Mesanovic S; Sahovic H; Simendic V
Med Arch; 2017 Feb; 71(1):20-24. PubMed ID: 28428668
[TBL] [Abstract][Full Text] [Related]
17. [Analysis of induction efficacy and prognostic factors in FLT3-ITD positive acute myeloid leukemia in the real world].
Jia JS; Zhu HH; Gong LZ; Zhao T; Wang J; Jiang Q; Huang XJ; Jiang H
Zhonghua Xue Ye Xue Za Zhi; 2019 May; 40(5):398-403. PubMed ID: 31207705
[No Abstract] [Full Text] [Related]
18. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461).
Byrd JC; Mrózek K; Dodge RK; Carroll AJ; Edwards CG; Arthur DC; Pettenati MJ; Patil SR; Rao KW; Watson MS; Koduru PR; Moore JO; Stone RM; Mayer RJ; Feldman EJ; Davey FR; Schiffer CA; Larson RA; Bloomfield CD;
Blood; 2002 Dec; 100(13):4325-36. PubMed ID: 12393746
[TBL] [Abstract][Full Text] [Related]
19. Early blast clearance by remission induction therapy is a major independent prognostic factor for both achievement of complete remission and long-term outcome in acute myeloid leukemia: data from the German AML Cooperative Group (AMLCG) 1992 Trial.
Kern W; Haferlach T; Schoch C; Loffler H; Gassmann W; Heinecke A; Sauerland MC; Berdel W; Buchner T; Hiddemann W
Blood; 2003 Jan; 101(1):64-70. PubMed ID: 12393605
[TBL] [Abstract][Full Text] [Related]
20. Abnormal cytogenetics at date of morphologic complete remission predicts short overall and disease-free survival, and higher relapse rate in adult acute myeloid leukemia: results from cancer and leukemia group B study 8461.
Marcucci G; Mrózek K; Ruppert AS; Archer KJ; Pettenati MJ; Heerema NA; Carroll AJ; Koduru PR; Kolitz JE; Sterling LJ; Edwards CG; Anastasi J; Larson RA; Bloomfield CD
J Clin Oncol; 2004 Jun; 22(12):2410-8. PubMed ID: 15197203
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
